Method for formulating large diameter synthetic membrane vesicles

Patent metadata

Field	Value
Publication number	US-10045941-B2
Application number	US-201313786873-A
Country	US
Kind code	B2
Filing date	Mar 6, 2013
Priority date	Apr 9, 2010
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

First claim

What is claimed is:

1. A process for preparing droplets using an atomizing nozzle apparatus, wherein the apparatus comprises: a first fluid conduit, a second fluid conduit, a third fluid conduit, and a fourth fluid conduit each having at least one entrance orifice and at least one exit orifice;
a first fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and said at least one entrance orifice connecting to the at least one exit orifice of the first fluid conduit and the at least one exit orifice of the second fluid conduit, wherein the second fluid conduit annularly surrounds a portion of the first fluid conduit, wherein the first fluid contacting chamber conically tapers from the top of the first fluid contacting chamber to the bottom of the first fluid contacting chamber;
a second fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and said at least one entrance orifice connecting to the at least one exit orifice of the first fluid contacting chamber and the at least one exit orifice of the third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the first fluid contacting chamber and wherein the diameter of the second fluid contacting chamber conically tapers from its top to its bottom, wherein the first and second fluid contacting chambers are hydraulic extrusion cones; and
the fourth fluid conduit, wherein the fourth fluid conduit annularly surrounds a portion of the second fluid contacting chamber,
wherein the process for preparing droplets comprises:
applying a first liquid to the first fluid conduit;
applying a second liquid to the second fluid conduit;
applying a third liquid to the third fluid conduit; and
applying a gas to the fourth fluid conduit,
wherein the gas exiting the fourth fluid conduit exit orifice impinges the liquid exiting the at least one exit orifice of the second fluid contacting chamber, providing atomized droplets, wherein the droplets have an average diameter from about 100 nm to about 100 μM.

2. The process of claim 1 , wherein:
the first liquid is an emulsion comprised of:
i) a discontinuous first aqueous phase; and
ii) a continuous first organic phase comprising a first organic solvent;

the second liquid is a second organic phase;
the third liquid is a second aqueous phase.

3. The process of claim 1 , wherein:
the first liquid is an emulsion comprised of:
i) a discontinuous first aqueous phase; and
ii) a continuous first organic phase comprising a first organic solvent;

the second liquid is a second aqueous phase;
the third liquid is a second organic phase.

4. The process of claim 2 , wherein the first organic solvent is chloroform or methylene chloride.

5. The process of claim 2 , wherein the first organic phase further comprises at least one amphipathic lipid and at least one neutral lipid.

6. The process of claim 1 , wherein the second liquid forms a sheath around the first liquid, the first liquid forming a first liquid core.

7. The process of claim 6 , wherein the second liquid sheath comprises a composition that is different from a composition of the first organic phase.

8. The process of claim 6 , wherein the first fluid contacting chamber decreases the diameter of the first liquid core and the second liquid.

9. The process of claim 6 , wherein the diameter of the second fluid contacting chamber conically tapers from its top to its bottom and the third liquid is constricted by the second fluid contacting chamber to create a concentric annular sheath around the first liquid core and the second liquid sheath.

10. The process of claim 2 , wherein the second organic phase comprises a charged lipid solution.

11. The process of claim 2 , wherein the atomized droplets comprise an outer layer and an internal membrane, the outer layer comprising a charged lipid and the internal membrane comprising a lipid.

12. The process of claim 2 , wherein the first organic phase further comprises a first lipid and the second organic phase comprises a second lipid and a second organic solvent.

13. The process of claim 12 , wherein the second lipid is the same type of lipid as the first lipid.

14. The process of claim 12 , wherein the second lipid is a different type of lipid than the first lipid.

15. The process of claim 12 , wherein the second organic solvent is the same type of solvent as the first organic solvent.

16. The process of claim 12 , wherein the second organic solvent is a different type of solvent than the first organic solvent.

17. The process of claim 2 , wherein the second organic phase comprises a polymer and an organic solvent.

18. The process of claim 2 , wherein the second organic phase comprises a polymer.

19. The process of claim 1 , wherein the third liquid is a buffer solution.

20. The process of claim 1 , wherein the first fluid travels at a first volumetric flow rate through the first fluid conduit, the second fluid travels at a second volumetric flow rate through the second fluid conduit, and the third fluid travels at a third volumetric flow rate through the third fluid conduit.

21. The process of claim 20 , wherein each of the first volumetric flow rate, second volumetric flow rate, and third volumetric flow rate is between 2 mL/minute and 1,000 mL/minute.

22. The process of claim 20 , wherein each of the first volumetric flow rate, second volumetric flow rate, and third volumetric flow rate is between 10 mL/minute and 500 mL/minute.

23. The process of claim 20 , wherein each of the first volumetric flow rate, second volumetric flow rate, and third volumetric flow rate is between 10 mL/minute and 100 mL/minute.

24. The process of claim 20 , wherein each of the first volumetric flow rate, second volumetric flow rate, and third volumetric flow rate is between 50 mL/minute and 100 mL/minute.

25. The process of claim 1 , wherein:
the first liquid is an aqueous phase comprising an active agent;
the second liquid is an organic phase comprising a lipid solution; and
the third liquid is a buffer solution.

26. The process of claim 1 , wherein:
the first liquid is a first aqueous phase;
the second liquid is an organic phase comprising phospholipids, a polymer, or a combination of phospholipids and a polymer in an organic solvent; and
the third liquid is a second aqueous phase.

Assignees

• Pacira Pharmaceuticals Inc

Inventors

• Schutt Ernest George
• Mcguire Ronald Warren
• Walters Peter Andrew
• Los Kathleen D A

Classifications

• A61P23/02

  Local anaesthetics · CPC title

• A61P23/00

  Anaesthetics · CPC title

• B01J13/043

  Drying and spraying · CPC title

• B01D1/16

  by spraying (B01D1/22 takes precedence) · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title